FDA Approves HYDROCODONE BITARTRATE AND ACETAMINOPHEN — PAI Holdings, LLC dba PAI Pharma

PAI Holdings has secured FDA approval for its ANDA 040838, facilitating the market launch of hydrocodone bitartrate and acetaminophen, a widely utilized generic pain reliever. This expansion of the company’s product portfolio is expected to significantly bolster revenue streams and strengthen its competitive position within the generic opioid market.